TheScreener - Wuxi Biologics (Cayman) Inc. (2269) WUXI BIO reduced its risk exposure resulting in an upgrade to Slightly Positive

Report

TheScreener

EUR 14.21 For Business Accounts Only

WUXI BIO reduced its risk exposure resulting in an upgrade to Slightly Positive

WUXI BIO (HK), a company active in the Pharmaceuticals industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date April 17, 2020, the closing price was HKD 116.50 and its potential was estimated at HKD 128.26.

18/04/2020 6 EN

Underlying

Wuxi Biologics (Cayman) Inc.

Wuxi Biologics Cayman Inc. WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company's primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs. The Company mainly distributes its products in the United States of America (USA) and the People's Republic of China (PRC) markets.

See profile

KYG970081090 Cayman Islands

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

SmartInsider

Wuxi Biologics (Cayman) Inc: 1 director

A director at Wuxi Biologics (Cayman) Inc bought 1,445,000 shares at 11.574HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. ...

Free Trial

June 25, 2024 June 25, 2024 1 EN

New Street Research

Global CDMO's - Quantifying the Aducanumab Windfall (20 pgs)

Whilst most people consider the US election outcome as the most important event this week, for millions of Alzheimer’s (AD) patients & their families, the Aducanumab FDA AdCom on Friday is likely to be more impactful. Our unique coverage of the biggest CDMO’s allows us to quantify the financial impact of a potential AD windfall from Biogen’s aducanumab. We believe Biogen will already have a shortlist of CDMO suppliers as we show they can only produce ~25% of the quantity required & the FDA will want them to source multiple suppliers. Our highly detailed analysis shows how much aducanumab will ...

EUR 4737.50

November 3, 2020 November 3, 2020 20 EN

UOB

Regional Morning Notes - Wednesday, October 21, 2020

GREATER CHINA Results China Yongda Automobile Services Holdings (3669 HK/BUY/HK$11.12/Target: HK$15.00): 3Q20: Net profit up 41% yoy, beating estimates; raise target price to HK$15.00. Update Cathay Pacific Airways (293 HK/BUY/HK$5.72/Target: HK$6.70): Time to add positions as travel bubbles form and CX restructures; Upgrade to BUY. The United Laboratories International Holdings: (3933 HK/BUY/HK$7.16/Target: HK$9.75): Continues with solid business expansion; targeting to secure a 15-20% insulin market share despite potential GPO risks. WuXi Biologics (Cayman) Inc (2269 HK/BUY/HK$201.60/Target:...

October 21, 2020 October 21, 2020 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

WUXI BIO reduced its risk exposure resulting in an upgrade to Slightly Positive

Empowering Investors

Wuxi Biologics (Cayman) Inc: 1 director

Global CDMO's - Quantifying the Aducanumab Windfall (20 pgs)

Regional Morning Notes - Wednesday, October 21, 2020

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe